Oxygen Biotherapeutics surges after FDA lifts hold on Oxycyte

Oxygen Biotherapeutics' (OXBT) shares soar 30% after the FDA verbally lifts a hold on clinical trials of the company's Oxycyte treatment for traumatic brain injury (TBI).

The FDA's decision comes after Oxygen submitted animal study data in September that addressed the agency's concerns about the use of Oxycyte. The studies assessed the product's interaction with the immune system and the risks of intracerebral hemorrhage.

Oxygen is enrolling patients in Israel for a Phase II-b study to evaluate the safety and tolerability of Oxycyte in patients with severe non-penetrating traumatic brain injury (STOP-TBI). (PR)

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs